View ValuationHubei DinglongLtd 将来の成長Future 基準チェック /56Hubei DinglongLtd利益と収益がそれぞれ年間30%と24.2%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に19.2% 30%なると予測されています。主要情報30.0%収益成長率29.97%EPS成長率Chemicals 収益成長30.6%収益成長率24.2%将来の株主資本利益率19.24%アナリストカバレッジLow最終更新日20 May 2026今後の成長に関する最新情報Major Estimate Revision • May 21Consensus revenue estimates fall by 10%The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from CN¥5.04b to CN¥4.51b. EPS estimate fell from CN¥1.12 to CN¥1.11 per share. Net income forecast to grow 36% next year vs 56% growth forecast for Chemicals industry in China. Consensus price target up from CN¥50.43 to CN¥71.10. Share price rose 5.0% to CN¥72.98 over the past week.Price Target Changed • Nov 24Price target increased by 12% to CN¥42.33Up from CN¥37.67, the current price target is an average from 3 analysts. New target price is 27% above last closing price of CN¥33.30. Stock is up 23% over the past year. The company is forecast to post earnings per share of CN¥0.74 for next year compared to CN¥0.56 last year.Price Target Changed • May 05Price target increased by 7.1% to CN¥35.00Up from CN¥32.67, the current price target is an average from 3 analysts. New target price is 17% above last closing price of CN¥29.80. Stock is up 26% over the past year. The company is forecast to post earnings per share of CN¥0.72 for next year compared to CN¥0.56 last year.Price Target Changed • Oct 28Price target increased by 17% to CN¥29.33Up from CN¥25.00, the current price target is an average from 3 analysts. New target price is 7.3% above last closing price of CN¥27.34. Stock is up 16% over the past year. The company is forecast to post earnings per share of CN¥0.52 for next year compared to CN¥0.24 last year.Major Estimate Revision • Apr 16Consensus EPS estimates fall by 14%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥3.27b to CN¥3.16b. EPS estimate also fell from CN¥0.508 per share to CN¥0.438 per share. Net income forecast to grow 86% next year vs 44% growth forecast for Chemicals industry in China. Consensus price target up from CN¥22.75 to CN¥25.50. Share price fell 6.7% to CN¥20.12 over the past week.Price Target Changed • Apr 11Price target increased by 7.7% to CN¥24.50Up from CN¥22.75, the current price target is an average from 2 analysts. New target price is 19% above last closing price of CN¥20.55. Stock is down 19% over the past year. The company is forecast to post earnings per share of CN¥0.43 for next year compared to CN¥0.24 last year.すべての更新を表示Recent updatesMajor Estimate Revision • May 21Consensus revenue estimates fall by 10%The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from CN¥5.04b to CN¥4.51b. EPS estimate fell from CN¥1.12 to CN¥1.11 per share. Net income forecast to grow 36% next year vs 56% growth forecast for Chemicals industry in China. Consensus price target up from CN¥50.43 to CN¥71.10. Share price rose 5.0% to CN¥72.98 over the past week.New Risk • May 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 10.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.Reported Earnings • Apr 28First quarter 2026 earnings released: EPS: CN¥0.26 (vs CN¥0.15 in 1Q 2025)First quarter 2026 results: EPS: CN¥0.26 (up from CN¥0.15 in 1Q 2025). Revenue: CN¥1.02b (up 24% from 1Q 2025). Net income: CN¥251.0m (up 78% from 1Q 2025). Profit margin: 25% (up from 17% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth.Board Change • Apr 23Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 3 highly experienced directors. Independent Director Xinping Xia was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Mar 31+ 1 more updateHubei Dinglong CO.,Ltd., Annual General Meeting, Apr 24, 2026Hubei Dinglong CO.,Ltd., Annual General Meeting, Apr 24, 2026, at 14:30 China Standard Time. Location: 6F, Executive Building 1, No. 1, Dongjinghe Road, Wuhan Economic and Technological Development Zone, Hubei ChinaBuy Or Sell Opportunity • Mar 27Now 41% overvalued after recent price riseOver the last 90 days, the stock has risen 38% to CN¥53.07. The fair value is estimated to be CN¥37.71, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 33%. Revenue is forecast to grow by 57% in 2 years. Earnings are forecast to grow by 79% in the next 2 years.Reported Earnings • Mar 27Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2025 results: EPS: CN¥0.77 (up from CN¥0.56 in FY 2024). Revenue: CN¥3.66b (up 9.7% from FY 2024). Net income: CN¥720.2m (up 38% from FY 2024). Profit margin: 20% (up from 16% in FY 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 6.1%. Earnings per share (EPS) exceeded analyst estimates by 1.7%. Revenue is forecast to grow 22% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 33% per year whereas the company’s share price has increased by 29% per year.Buy Or Sell Opportunity • Mar 12Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 21% to CN¥45.12. The fair value is estimated to be CN¥37.32, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 27%. Revenue is forecast to grow by 53% in 2 years. Earnings are forecast to grow by 80% in the next 2 years.Buy Or Sell Opportunity • Feb 03Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 26% to CN¥43.72. The fair value is estimated to be CN¥35.63, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 27%. Revenue is forecast to grow by 53% in 2 years. Earnings are forecast to grow by 80% in the next 2 years.Buy Or Sell Opportunity • Jan 07Now 26% overvalued after recent price riseOver the last 90 days, the stock has risen 22% to CN¥44.83. The fair value is estimated to be CN¥35.70, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 27%. Revenue is forecast to grow by 53% in 2 years. Earnings are forecast to grow by 80% in the next 2 years.お知らせ • Dec 31Hubei Dinglong CO.,Ltd. to Report Fiscal Year 2025 Results on Mar 27, 2026Hubei Dinglong CO.,Ltd. announced that they will report fiscal year 2025 results on Mar 27, 2026Price Target Changed • Nov 24Price target increased by 12% to CN¥42.33Up from CN¥37.67, the current price target is an average from 3 analysts. New target price is 27% above last closing price of CN¥33.30. Stock is up 23% over the past year. The company is forecast to post earnings per share of CN¥0.74 for next year compared to CN¥0.56 last year.Reported Earnings • Oct 28Third quarter 2025 earnings released: EPS: CN¥0.22 (vs CN¥0.17 in 3Q 2024)Third quarter 2025 results: EPS: CN¥0.22 (up from CN¥0.17 in 3Q 2024). Revenue: CN¥966.5m (up 6.6% from 3Q 2024). Net income: CN¥208.4m (up 32% from 3Q 2024). Profit margin: 22% (up from 18% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.お知らせ • Sep 30Hubei Dinglong CO.,Ltd. to Report Q3, 2025 Results on Oct 28, 2025Hubei Dinglong CO.,Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025Valuation Update With 7 Day Price Move • Sep 24Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CN¥37.00, the stock trades at a forward P/E ratio of 43x. Average forward P/E is 23x in the Chemicals industry in China. Total returns to shareholders of 55% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥26.74 per share.Buy Or Sell Opportunity • Sep 17Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 17% to CN¥31.97. The fair value is estimated to be CN¥26.62, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to grow by 46% in 2 years. Earnings are forecast to grow by 77% in the next 2 years.Buy Or Sell Opportunity • Aug 23Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 16% to CN¥32.51. The fair value is estimated to be CN¥26.89, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to grow by 46% in 2 years. Earnings are forecast to grow by 77% in the next 2 years.お知らせ • Jul 02Hubei Dinglong CO.,Ltd. to Report First Half, 2025 Results on Aug 22, 2025Hubei Dinglong CO.,Ltd. announced that they will report first half, 2025 results on Aug 22, 2025お知らせ • Jun 13Hubei Dinglong CO.,Ltd. (SZSE:300054) agreed to acquire Hubei Dinghui Microelectronic Materials Co., Ltd. from CCB Trust Co., Ltd. for CNY 240 million.Hubei Dinglong CO.,Ltd. (SZSE:300054) agreed to acquire Hubei Dinghui Microelectronic Materials Co., Ltd. from CCB Trust Co., Ltd. for CNY 240 million on June 10, 2025. A cash consideration of CNY 240 million will be paid by Hubei Dinglong CO.,Ltd. As part of consideration, CNY 240 million is paid towards common equity of Hubei Dinghui Microelectronic Materials Co., Ltd. Upon completion, Hubei Dinglong CO.,Ltd. will own 99.35% stake in Hubei Dinghui Microelectronic Materials Co., Ltd. For the period ending December 31, 2024, Hubei Dinghui Microelectronic Materials Co., Ltd. reported total revenue of CNY 717.23 million. As of December 31, 2024, Hubei Dinghui Microelectronic Materials Co., Ltd. reported total assets of CNY 1.35 billion and total common equity of CNY 963.08 million. The transaction has been approved by the board of Hubei Dinglong CO.,Ltd.お知らせ • May 22Hubei Dinglong Co.,Ltd. Approves Cash Dividend for the Year 2024Hubei Dinglong CO.,Ltd. held its Annual General Meeting of 2024 on 20 May 2025, during which the following proposal(s) was/were approved: 2024 profit distribution plan of Cash dividend/10 shares (tax included): CNY 1.00000000.Price Target Changed • May 05Price target increased by 7.1% to CN¥35.00Up from CN¥32.67, the current price target is an average from 3 analysts. New target price is 17% above last closing price of CN¥29.80. Stock is up 26% over the past year. The company is forecast to post earnings per share of CN¥0.72 for next year compared to CN¥0.56 last year.Reported Earnings • May 02First quarter 2025 earnings released: EPS: CN¥0.15 (vs CN¥0.086 in 1Q 2024)First quarter 2025 results: EPS: CN¥0.15 (up from CN¥0.086 in 1Q 2024). Revenue: CN¥823.9m (up 16% from 1Q 2024). Net income: CN¥141.0m (up 73% from 1Q 2024). Profit margin: 17% (up from 12% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 21% per year.お知らせ • Apr 29Hubei Dinglong CO.,Ltd., Annual General Meeting, May 20, 2025Hubei Dinglong CO.,Ltd., Annual General Meeting, May 20, 2025, at 15:00 China Standard Time.Buy Or Sell Opportunity • Apr 11Now 26% overvalued after recent price riseOver the last 90 days, the stock has risen 16% to CN¥29.50. The fair value is estimated to be CN¥23.35, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.2% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 40% in 2 years. Earnings are forecast to grow by 98% in the next 2 years.お知らせ • Mar 31Hubei Dinglong CO.,Ltd. to Report Q1, 2025 Results on Apr 29, 2025Hubei Dinglong CO.,Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025Buy Or Sell Opportunity • Mar 24Now 24% overvalued after recent price riseOver the last 90 days, the stock has risen 4.9% to CN¥28.32. The fair value is estimated to be CN¥22.81, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.2% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 39% in 2 years. Earnings are forecast to grow by 97% in the next 2 years.Valuation Update With 7 Day Price Move • Feb 20Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥30.38, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 19x in the Chemicals industry in China. Total returns to shareholders of 43% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥22.59 per share.Buy Or Sell Opportunity • Feb 12Now 21% overvaluedOver the last 90 days, the stock has fallen 4.4% to CN¥27.23. The fair value is estimated to be CN¥22.57, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.2% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 39% in 2 years. Earnings are forecast to grow by 98% in the next 2 years.お知らせ • Dec 31Hubei Dinglong CO.,Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025Hubei Dinglong CO.,Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025Buy Or Sell Opportunity • Nov 08Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 42% to CN¥29.00. The fair value is estimated to be CN¥23.93, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.2% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 39% in 2 years. Earnings are forecast to grow by 98% in the next 2 years.Price Target Changed • Oct 28Price target increased by 17% to CN¥29.33Up from CN¥25.00, the current price target is an average from 3 analysts. New target price is 7.3% above last closing price of CN¥27.34. Stock is up 16% over the past year. The company is forecast to post earnings per share of CN¥0.52 for next year compared to CN¥0.24 last year.Reported Earnings • Oct 25Third quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.093 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.17 (up from CN¥0.093 in 3Q 2023). Revenue: CN¥906.9m (up 27% from 3Q 2023). Net income: CN¥158.5m (up 97% from 3Q 2023). Profit margin: 18% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.お知らせ • Sep 30Hubei Dinglong CO.,Ltd. to Report Q3, 2024 Results on Oct 25, 2024Hubei Dinglong CO.,Ltd. announced that they will report Q3, 2024 results on Oct 25, 2024Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 30%After last week's 30% share price gain to CN¥23.85, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 26% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥13.33 per share.Reported Earnings • Aug 20Second quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.063 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.14 (up from CN¥0.063 in 2Q 2023). Revenue: CN¥810.8m (up 32% from 2Q 2023). Net income: CN¥136.3m (up 123% from 2Q 2023). Profit margin: 17% (up from 10.0% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.お知らせ • Jun 29Hubei Dinglong CO.,Ltd. to Report First Half, 2024 Results on Aug 20, 2024Hubei Dinglong CO.,Ltd. announced that they will report first half, 2024 results on Aug 20, 2024Reported Earnings • Apr 26First quarter 2024 earnings released: EPS: CN¥0.086 (vs CN¥0.037 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.086 (up from CN¥0.037 in 1Q 2023). Revenue: CN¥708.0m (up 30% from 1Q 2023). Net income: CN¥81.6m (up 135% from 1Q 2023). Profit margin: 12% (up from 6.4% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.Major Estimate Revision • Apr 16Consensus EPS estimates fall by 14%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥3.27b to CN¥3.16b. EPS estimate also fell from CN¥0.508 per share to CN¥0.438 per share. Net income forecast to grow 86% next year vs 44% growth forecast for Chemicals industry in China. Consensus price target up from CN¥22.75 to CN¥25.50. Share price fell 6.7% to CN¥20.12 over the past week.Price Target Changed • Apr 11Price target increased by 7.7% to CN¥24.50Up from CN¥22.75, the current price target is an average from 2 analysts. New target price is 19% above last closing price of CN¥20.55. Stock is down 19% over the past year. The company is forecast to post earnings per share of CN¥0.43 for next year compared to CN¥0.24 last year.お知らせ • Apr 10Hubei Dinglong CO.,Ltd., Annual General Meeting, May 14, 2024Hubei Dinglong CO.,Ltd., Annual General Meeting, May 14, 2024, at 15:00 China Standard Time. Location: The Company's Meeting Room, Wuhan, Hubei ChinaReported Earnings • Apr 10Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: EPS: CN¥0.24 (down from CN¥0.42 in FY 2022). Revenue: CN¥2.67b (down 2.0% from FY 2022). Net income: CN¥222.0m (down 43% from FY 2022). Profit margin: 8.3% (down from 14% in FY 2022). The decrease in margin was primarily driven by higher expenses. Revenue missed analyst estimates by 3.3%. Earnings per share (EPS) also missed analyst estimates by 4.7%. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.お知らせ • Mar 30Hubei Dinglong CO.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024Hubei Dinglong CO.,Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024Buy Or Sell Opportunity • Mar 26Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 10% to CN¥21.51. The fair value is estimated to be CN¥27.39, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 73%. Revenue is forecast to grow by 40% in 2 years. Earnings are forecast to grow by 116% in the next 2 years.お知らせ • Mar 16Hubei Dinglong CO.,Ltd. (SZSE:300054) agreed to acquire 6.83% stake in Wuhan Rouxian Technology Co., Ltd. from Qushui Dinglong Taihao Enterprise Management Co., Ltd. managed by Wuhan Paradise Silicon Valley Technology Innovation Asset Management Co., Ltd. for CNY 31.9 million.Hubei Dinglong CO.,Ltd. (SZSE:300054) agreed to acquire 6.83% stake in Wuhan Rouxian Technology Co., Ltd. from Qushui Dinglong Taihao Enterprise Management Co., Ltd. managed by Wuhan Paradise Silicon Valley Technology Innovation Asset Management Co., Ltd. for CNY 31.9 million on March 13, 2024. Transaction was financed by Hubei Dinglong's own funds. Transaction has already been approved by Wuhan Rouxian Technology Co., Ltd's board of director's.Valuation Update With 7 Day Price Move • Feb 08Investor sentiment improves as stock rises 17%After last week's 17% share price gain to CN¥20.42, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 13x in the Chemicals industry in China. Negligible returns to shareholders over past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥27.64 per share.お知らせ • Feb 07Hubei Dinglong CO.,Ltd. (SZSE:300054) announces an Equity Buyback for CNY 200 million worth of its shares.Hubei Dinglong CO.,Ltd. (SZSE:300054) announces a share repurchase program. Under the program, the company will repurchase up to CNY 200 million worth of its shares. The shares will be repurchased at a price not more than CNY 30 per share. The purpose of the program is to use the repurchased shares for ESOP or equity incentives. The program is valid for a period of 3 months.Price Target Changed • Feb 02Price target decreased by 8.1% to CN¥22.75Down from CN¥24.75, the current price target is an average from 2 analysts. New target price is 37% above last closing price of CN¥16.61. Stock is down 29% over the past year. The company is forecast to post earnings per share of CN¥0.25 for next year compared to CN¥0.42 last year.Major Estimate Revision • Jan 25Consensus EPS estimates fall by 20%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from CN¥0.32 to CN¥0.255. Revenue forecast unchanged from CN¥2.77b at last update. Net income forecast to grow 59% next year vs 59% growth forecast for Chemicals industry in China. Consensus price target down from CN¥25.50 to CN¥24.75. Share price fell 2.4% to CN¥19.26 over the past week.お知らせ • Dec 30Hubei Dinglong CO.,Ltd. to Report Fiscal Year 2023 Results on Apr 10, 2024Hubei Dinglong CO.,Ltd. announced that they will report fiscal year 2023 results on Apr 10, 2024Reported Earnings • Oct 26Third quarter 2023 earnings released: EPS: CN¥0.093 (vs CN¥0.10 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.093 (down from CN¥0.10 in 3Q 2022). Revenue: CN¥713.2m (up 11% from 3Q 2022). Net income: CN¥80.4m (down 20% from 3Q 2022). Profit margin: 11% (down from 16% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.お知らせ • Sep 30Hubei Dinglong CO.,Ltd. to Report Q3, 2023 Results on Oct 26, 2023Hubei Dinglong CO.,Ltd. announced that they will report Q3, 2023 results on Oct 26, 2023Major Estimate Revision • Aug 25Consensus EPS estimates fall by 12%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from CN¥3.19b to CN¥3.06b. EPS estimate also fell from CN¥0.533 per share to CN¥0.467 per share. Net income forecast to grow 80% next year vs 53% growth forecast for Chemicals industry in China. Consensus price target down from CN¥30.00 to CN¥27.50. Share price fell 4.5% to CN¥20.46 over the past week.Price Target Changed • Aug 22Price target decreased by 8.3% to CN¥27.50Down from CN¥30.00, the current price target is an average from 4 analysts. New target price is 27% above last closing price of CN¥21.65. Stock is down 15% over the past year. The company is forecast to post earnings per share of CN¥0.50 for next year compared to CN¥0.42 last year.Reported Earnings • Aug 19Second quarter 2023 earnings released: EPS: CN¥0.063 (vs CN¥0.13 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.063 (down from CN¥0.13 in 2Q 2022). Revenue: CN¥612.7m (down 18% from 2Q 2022). Net income: CN¥61.1m (down 50% from 2Q 2022). Profit margin: 10.0% (down from 17% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.お知らせ • Jul 01Hubei Dinglong CO.,Ltd. to Report First Half, 2023 Results on Aug 19, 2023Hubei Dinglong CO.,Ltd. announced that they will report first half, 2023 results on Aug 19, 2023お知らせ • Jun 09Hubei Dinglong Co.,Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on June 16, 2023Hubei Dinglong CO.,Ltd. announced final cash dividend/10 shares (tax included) of CNY 0.50000000 on A shares for the year 2022. Record date is June 15, 2023. Ex-date is May June 16, 2023. Payment date is June 16, 2023.Valuation Update With 7 Day Price Move • Apr 20Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥29.90, the stock trades at a forward P/E ratio of 51x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 162% over the past three years.Reported Earnings • Apr 12Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: EPS: CN¥0.42 (up from CN¥0.23 in FY 2021). Revenue: CN¥2.72b (up 16% from FY 2021). Net income: CN¥390.0m (up 83% from FY 2021). Profit margin: 14% (up from 9.1% in FY 2021). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 4.2%. Earnings per share (EPS) also missed analyst estimates by 3.7%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth.Price Target Changed • Jan 11Price target increased to CN¥27.75Up from CN¥25.92, the current price target is an average from 2 analysts. New target price is 26% above last closing price of CN¥21.96. Stock is down 1.6% over the past year. The company is forecast to post earnings per share of CN¥0.42 for next year compared to CN¥0.23 last year.Board Change • Nov 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Independent Director Minguang Su was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 27Third quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.062 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.10 (up from CN¥0.062 in 3Q 2021). Revenue: CN¥642.9m (up 16% from 3Q 2021). Net income: CN¥100.3m (up 70% from 3Q 2021). Profit margin: 16% (up from 11% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 31% per year whereas the company’s share price has increased by 33% per year.Valuation Update With 7 Day Price Move • Oct 11Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to CN¥19.19, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 14x in the Chemicals industry in China. Total returns to shareholders of 108% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥17.38 per share.Valuation Update With 7 Day Price Move • Sep 07Investor sentiment improved over the past weekAfter last week's 17% share price gain to CN¥26.51, the stock trades at a forward P/E ratio of 52x. Average forward P/E is 17x in the Chemicals industry in China. Total returns to shareholders of 154% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥19.08 per share.Reported Earnings • Aug 20Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.058 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.14 (up from CN¥0.058 in 2Q 2021). Revenue: CN¥742.8m (up 29% from 2Q 2021). Net income: CN¥123.1m (up 129% from 2Q 2021). Profit margin: 17% (up from 9.3% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 29%, compared to a 41% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 38% per year, which means it is well ahead of earnings.お知らせ • Jun 18Hubei Dinglong Co.,Ltd. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on June 24, 2022Hubei Dinglong CO.,Ltd. announced 2021 final profit distribution plan to be implemented (A shares), Payable on June 24, 2022. The company announced Cash dividend/10 shares (tax included) of CNY 0.20000000. The record date is June 23, 2022 and ex-date is June 24, 2022.Board Change • Jun 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Independent Director Minguang Su was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 12+ 1 more updateHubei Dinglong CO.,Ltd. Announces Executive ChangesHubei Dinglong CO.,Ltd. at the AGM, the shareholders approved election of Zhu Shuangquan, Zhu Shunquan, Yang Bo, Yao Hong, Yang Pingcai, Su Minguang. The following election and nomination of independent directors, cumulative voting system applicable: Huang Jing, Yu Minggui, Wang Xiongyuan.Reported Earnings • Apr 27First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2022 results: EPS: CN¥0.076 (up from CN¥0.04 in 1Q 2021). Revenue: CN¥569.7m (up 9.6% from 1Q 2021). Net income: CN¥71.4m (up 90% from 1Q 2021). Profit margin: 13% (up from 7.2% in 1Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 4.1%. Earnings per share (EPS) missed analyst estimates by 16%. Over the next year, revenue is forecast to grow 29%, compared to a 43% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. 3 independent directors (8 non-independent directors). Independent Director Xiao Ji was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Apr 23Hubei Dinglong CO.,Ltd. (SZSE:300054) announces an Equity Buyback for CNY 400 million worth of its shares.Hubei Dinglong CO.,Ltd. (SZSE:300054) announces a share repurchase program. Under the program, the company will repurchase up to CNY 400 million worth of its shares. The program is valid for a period of 12 months.お知らせ • Apr 16+ 1 more updateHubei Dinglong CO.,Ltd. Announces Profit Distribution Proposal for 2021Hubei Dinglong CO.,Ltd. announced on 15 April 2022 Cash dividend/10 shares (tax included) of CNY 0.20000000 for 2021.Reported Earnings • Apr 16Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: EPS: CN¥0.23 (up from CN¥0.17 loss in FY 2020). Revenue: CN¥2.36b (up 30% from FY 2020). Net income: CN¥213.5m (up CN¥373.3m from FY 2020). Profit margin: 9.1% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 4.1%. Earnings per share (EPS) missed analyst estimates by 16%. Over the next year, revenue is forecast to grow 15%, compared to a 51% growth forecast for the industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 105 percentage points per year, which is a significant difference in performance.お知らせ • Nov 24Hubei Dinglong CO.,Ltd. announced that it expects to receive CNY 210.5 million in funding from CCB Trust Co., Ltd.Hubei Dinglong CO.,Ltd. announced a private placement of common shares for a gross proceeds of CNY 210,500,000 on November 22, 2021. The transaction will include participation from CCB Trust Co., Ltd. Post transaction, the investor will hold a stake of 8%.Reported Earnings • Oct 28Third quarter 2021 earnings released: EPS CN¥0.062 (vs CN¥0.04 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥554.9m (up 25% from 3Q 2020). Net income: CN¥59.2m (up 45% from 3Q 2020). Profit margin: 11% (up from 9.2% in 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 158 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 19Second quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.18 in 2Q 2020)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥576.4m (up 9.2% from 2Q 2020). Net income: CN¥53.9m (down 71% from 2Q 2020). Profit margin: 9.3% (down from 35% in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 139 percentage points per year, which is a significant difference in performance.Reported Earnings • Apr 10Full year 2020 earnings released: CN¥0.17 loss per share (vs CN¥0.036 profit in FY 2019)The company reported a mediocre full year result with weaker earnings and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: CN¥1.82b (up 58% from FY 2019). Net loss: CN¥159.8m (down CN¥193.9m from profit in FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 82 percentage points per year, which is a significant difference in performance.お知らせ • Feb 24Hubei Dinglong CO.,Ltd. to Report Fiscal Year 2020 Results on Apr 10, 2021Hubei Dinglong CO.,Ltd. announced that they will report fiscal year 2020 results on Apr 10, 2021Is New 90 Day High Low • Jan 21New 90-day high: CN¥23.44The company is up 52% from its price of CN¥15.38 on 23 October 2020. The Chinese market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 19% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥12.87 per share.業績と収益の成長予測SZSE:300054 - アナリストの将来予測と過去の財務データ ( )CNY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20287,6291,9871,8122,362212/31/20275,9581,3871,2281,647412/31/20264,5141,0487531,53313/31/20263,8568305161,201N/A12/31/20253,6607203811,157N/A9/30/20253,610664128990N/A6/30/20253,550614103926N/A3/31/20253,454580102904N/A12/31/20243,33852160828N/A9/30/20243,220422-71780N/A6/30/20243,027344-303677N/A3/31/20242,828269-436619N/A12/31/20232,667222-494534N/A9/30/20232,639272-537440N/A6/30/20232,568291-393489N/A3/31/20232,698353-176572N/A12/31/20222,721390-113563N/A9/30/20222,660358-57525N/A6/30/20222,572317-153331N/A3/31/20222,406247-327139N/A12/31/20212,356214-3693N/A9/30/20212,214-249-34257N/A6/30/20212,102-268-24261N/A3/31/20212,054-13761292N/A12/31/20201,817-160181389N/A9/30/20201,60698-137116N/A6/30/20201,40193-52155N/A3/31/20201,161-55197N/A12/31/20191,14934N/A198N/A9/30/20191,146240N/A308N/A6/30/20191,224302N/A338N/A3/31/20191,292298N/A327N/A12/31/20181,338293N/A298N/A9/30/20181,443339N/A296N/A6/30/20181,528312N/A287N/A3/31/20181,626311N/A289N/A12/31/20171,700336N/A346N/A9/30/20171,632294N/A278N/A6/30/20171,624296N/A280N/A3/31/20171,457272N/A286N/A12/31/20161,306240N/A296N/A9/30/20161,215218N/A251N/A6/30/20161,083186N/A208N/A3/31/20161,051163N/A144N/A12/31/20151,050159N/A117N/A9/30/20151,007155N/A160N/A6/30/2015980145N/A129N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 300054の予測収益成長率 (年間30% ) は 貯蓄率 ( 2.4% ) を上回っています。収益対市場: 300054の収益 ( 30% ) はCN市場 ( 27.2% ) よりも速いペースで成長すると予測されています。高成長収益: 300054の収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: 300054の収益 ( 24.2% ) CN市場 ( 16.2% ) よりも速いペースで成長すると予測されています。高い収益成長: 300054の収益 ( 24.2% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 300054の 自己資本利益率 は、3年後には低くなると予測されています ( 19.2 %)。成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 11:45終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Hubei Dinglong CO.,Ltd. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関null nullChina International Capital Corporation LimitedYilin HouChina International Capital Corporation LimitedAda WangChina Stock Investment Research Co. Ltd. (GZ500..com)6 その他のアナリストを表示
Major Estimate Revision • May 21Consensus revenue estimates fall by 10%The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from CN¥5.04b to CN¥4.51b. EPS estimate fell from CN¥1.12 to CN¥1.11 per share. Net income forecast to grow 36% next year vs 56% growth forecast for Chemicals industry in China. Consensus price target up from CN¥50.43 to CN¥71.10. Share price rose 5.0% to CN¥72.98 over the past week.
Price Target Changed • Nov 24Price target increased by 12% to CN¥42.33Up from CN¥37.67, the current price target is an average from 3 analysts. New target price is 27% above last closing price of CN¥33.30. Stock is up 23% over the past year. The company is forecast to post earnings per share of CN¥0.74 for next year compared to CN¥0.56 last year.
Price Target Changed • May 05Price target increased by 7.1% to CN¥35.00Up from CN¥32.67, the current price target is an average from 3 analysts. New target price is 17% above last closing price of CN¥29.80. Stock is up 26% over the past year. The company is forecast to post earnings per share of CN¥0.72 for next year compared to CN¥0.56 last year.
Price Target Changed • Oct 28Price target increased by 17% to CN¥29.33Up from CN¥25.00, the current price target is an average from 3 analysts. New target price is 7.3% above last closing price of CN¥27.34. Stock is up 16% over the past year. The company is forecast to post earnings per share of CN¥0.52 for next year compared to CN¥0.24 last year.
Major Estimate Revision • Apr 16Consensus EPS estimates fall by 14%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥3.27b to CN¥3.16b. EPS estimate also fell from CN¥0.508 per share to CN¥0.438 per share. Net income forecast to grow 86% next year vs 44% growth forecast for Chemicals industry in China. Consensus price target up from CN¥22.75 to CN¥25.50. Share price fell 6.7% to CN¥20.12 over the past week.
Price Target Changed • Apr 11Price target increased by 7.7% to CN¥24.50Up from CN¥22.75, the current price target is an average from 2 analysts. New target price is 19% above last closing price of CN¥20.55. Stock is down 19% over the past year. The company is forecast to post earnings per share of CN¥0.43 for next year compared to CN¥0.24 last year.
Major Estimate Revision • May 21Consensus revenue estimates fall by 10%The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from CN¥5.04b to CN¥4.51b. EPS estimate fell from CN¥1.12 to CN¥1.11 per share. Net income forecast to grow 36% next year vs 56% growth forecast for Chemicals industry in China. Consensus price target up from CN¥50.43 to CN¥71.10. Share price rose 5.0% to CN¥72.98 over the past week.
New Risk • May 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 10.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
Reported Earnings • Apr 28First quarter 2026 earnings released: EPS: CN¥0.26 (vs CN¥0.15 in 1Q 2025)First quarter 2026 results: EPS: CN¥0.26 (up from CN¥0.15 in 1Q 2025). Revenue: CN¥1.02b (up 24% from 1Q 2025). Net income: CN¥251.0m (up 78% from 1Q 2025). Profit margin: 25% (up from 17% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth.
Board Change • Apr 23Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 3 highly experienced directors. Independent Director Xinping Xia was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 31+ 1 more updateHubei Dinglong CO.,Ltd., Annual General Meeting, Apr 24, 2026Hubei Dinglong CO.,Ltd., Annual General Meeting, Apr 24, 2026, at 14:30 China Standard Time. Location: 6F, Executive Building 1, No. 1, Dongjinghe Road, Wuhan Economic and Technological Development Zone, Hubei China
Buy Or Sell Opportunity • Mar 27Now 41% overvalued after recent price riseOver the last 90 days, the stock has risen 38% to CN¥53.07. The fair value is estimated to be CN¥37.71, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 33%. Revenue is forecast to grow by 57% in 2 years. Earnings are forecast to grow by 79% in the next 2 years.
Reported Earnings • Mar 27Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2025 results: EPS: CN¥0.77 (up from CN¥0.56 in FY 2024). Revenue: CN¥3.66b (up 9.7% from FY 2024). Net income: CN¥720.2m (up 38% from FY 2024). Profit margin: 20% (up from 16% in FY 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 6.1%. Earnings per share (EPS) exceeded analyst estimates by 1.7%. Revenue is forecast to grow 22% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 33% per year whereas the company’s share price has increased by 29% per year.
Buy Or Sell Opportunity • Mar 12Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 21% to CN¥45.12. The fair value is estimated to be CN¥37.32, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 27%. Revenue is forecast to grow by 53% in 2 years. Earnings are forecast to grow by 80% in the next 2 years.
Buy Or Sell Opportunity • Feb 03Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 26% to CN¥43.72. The fair value is estimated to be CN¥35.63, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 27%. Revenue is forecast to grow by 53% in 2 years. Earnings are forecast to grow by 80% in the next 2 years.
Buy Or Sell Opportunity • Jan 07Now 26% overvalued after recent price riseOver the last 90 days, the stock has risen 22% to CN¥44.83. The fair value is estimated to be CN¥35.70, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 27%. Revenue is forecast to grow by 53% in 2 years. Earnings are forecast to grow by 80% in the next 2 years.
お知らせ • Dec 31Hubei Dinglong CO.,Ltd. to Report Fiscal Year 2025 Results on Mar 27, 2026Hubei Dinglong CO.,Ltd. announced that they will report fiscal year 2025 results on Mar 27, 2026
Price Target Changed • Nov 24Price target increased by 12% to CN¥42.33Up from CN¥37.67, the current price target is an average from 3 analysts. New target price is 27% above last closing price of CN¥33.30. Stock is up 23% over the past year. The company is forecast to post earnings per share of CN¥0.74 for next year compared to CN¥0.56 last year.
Reported Earnings • Oct 28Third quarter 2025 earnings released: EPS: CN¥0.22 (vs CN¥0.17 in 3Q 2024)Third quarter 2025 results: EPS: CN¥0.22 (up from CN¥0.17 in 3Q 2024). Revenue: CN¥966.5m (up 6.6% from 3Q 2024). Net income: CN¥208.4m (up 32% from 3Q 2024). Profit margin: 22% (up from 18% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.
お知らせ • Sep 30Hubei Dinglong CO.,Ltd. to Report Q3, 2025 Results on Oct 28, 2025Hubei Dinglong CO.,Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025
Valuation Update With 7 Day Price Move • Sep 24Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CN¥37.00, the stock trades at a forward P/E ratio of 43x. Average forward P/E is 23x in the Chemicals industry in China. Total returns to shareholders of 55% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥26.74 per share.
Buy Or Sell Opportunity • Sep 17Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 17% to CN¥31.97. The fair value is estimated to be CN¥26.62, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to grow by 46% in 2 years. Earnings are forecast to grow by 77% in the next 2 years.
Buy Or Sell Opportunity • Aug 23Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 16% to CN¥32.51. The fair value is estimated to be CN¥26.89, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to grow by 46% in 2 years. Earnings are forecast to grow by 77% in the next 2 years.
お知らせ • Jul 02Hubei Dinglong CO.,Ltd. to Report First Half, 2025 Results on Aug 22, 2025Hubei Dinglong CO.,Ltd. announced that they will report first half, 2025 results on Aug 22, 2025
お知らせ • Jun 13Hubei Dinglong CO.,Ltd. (SZSE:300054) agreed to acquire Hubei Dinghui Microelectronic Materials Co., Ltd. from CCB Trust Co., Ltd. for CNY 240 million.Hubei Dinglong CO.,Ltd. (SZSE:300054) agreed to acquire Hubei Dinghui Microelectronic Materials Co., Ltd. from CCB Trust Co., Ltd. for CNY 240 million on June 10, 2025. A cash consideration of CNY 240 million will be paid by Hubei Dinglong CO.,Ltd. As part of consideration, CNY 240 million is paid towards common equity of Hubei Dinghui Microelectronic Materials Co., Ltd. Upon completion, Hubei Dinglong CO.,Ltd. will own 99.35% stake in Hubei Dinghui Microelectronic Materials Co., Ltd. For the period ending December 31, 2024, Hubei Dinghui Microelectronic Materials Co., Ltd. reported total revenue of CNY 717.23 million. As of December 31, 2024, Hubei Dinghui Microelectronic Materials Co., Ltd. reported total assets of CNY 1.35 billion and total common equity of CNY 963.08 million. The transaction has been approved by the board of Hubei Dinglong CO.,Ltd.
お知らせ • May 22Hubei Dinglong Co.,Ltd. Approves Cash Dividend for the Year 2024Hubei Dinglong CO.,Ltd. held its Annual General Meeting of 2024 on 20 May 2025, during which the following proposal(s) was/were approved: 2024 profit distribution plan of Cash dividend/10 shares (tax included): CNY 1.00000000.
Price Target Changed • May 05Price target increased by 7.1% to CN¥35.00Up from CN¥32.67, the current price target is an average from 3 analysts. New target price is 17% above last closing price of CN¥29.80. Stock is up 26% over the past year. The company is forecast to post earnings per share of CN¥0.72 for next year compared to CN¥0.56 last year.
Reported Earnings • May 02First quarter 2025 earnings released: EPS: CN¥0.15 (vs CN¥0.086 in 1Q 2024)First quarter 2025 results: EPS: CN¥0.15 (up from CN¥0.086 in 1Q 2024). Revenue: CN¥823.9m (up 16% from 1Q 2024). Net income: CN¥141.0m (up 73% from 1Q 2024). Profit margin: 17% (up from 12% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 21% per year.
お知らせ • Apr 29Hubei Dinglong CO.,Ltd., Annual General Meeting, May 20, 2025Hubei Dinglong CO.,Ltd., Annual General Meeting, May 20, 2025, at 15:00 China Standard Time.
Buy Or Sell Opportunity • Apr 11Now 26% overvalued after recent price riseOver the last 90 days, the stock has risen 16% to CN¥29.50. The fair value is estimated to be CN¥23.35, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.2% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 40% in 2 years. Earnings are forecast to grow by 98% in the next 2 years.
お知らせ • Mar 31Hubei Dinglong CO.,Ltd. to Report Q1, 2025 Results on Apr 29, 2025Hubei Dinglong CO.,Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025
Buy Or Sell Opportunity • Mar 24Now 24% overvalued after recent price riseOver the last 90 days, the stock has risen 4.9% to CN¥28.32. The fair value is estimated to be CN¥22.81, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.2% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 39% in 2 years. Earnings are forecast to grow by 97% in the next 2 years.
Valuation Update With 7 Day Price Move • Feb 20Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥30.38, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 19x in the Chemicals industry in China. Total returns to shareholders of 43% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥22.59 per share.
Buy Or Sell Opportunity • Feb 12Now 21% overvaluedOver the last 90 days, the stock has fallen 4.4% to CN¥27.23. The fair value is estimated to be CN¥22.57, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.2% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 39% in 2 years. Earnings are forecast to grow by 98% in the next 2 years.
お知らせ • Dec 31Hubei Dinglong CO.,Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025Hubei Dinglong CO.,Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025
Buy Or Sell Opportunity • Nov 08Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 42% to CN¥29.00. The fair value is estimated to be CN¥23.93, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.2% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 39% in 2 years. Earnings are forecast to grow by 98% in the next 2 years.
Price Target Changed • Oct 28Price target increased by 17% to CN¥29.33Up from CN¥25.00, the current price target is an average from 3 analysts. New target price is 7.3% above last closing price of CN¥27.34. Stock is up 16% over the past year. The company is forecast to post earnings per share of CN¥0.52 for next year compared to CN¥0.24 last year.
Reported Earnings • Oct 25Third quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.093 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.17 (up from CN¥0.093 in 3Q 2023). Revenue: CN¥906.9m (up 27% from 3Q 2023). Net income: CN¥158.5m (up 97% from 3Q 2023). Profit margin: 18% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.
お知らせ • Sep 30Hubei Dinglong CO.,Ltd. to Report Q3, 2024 Results on Oct 25, 2024Hubei Dinglong CO.,Ltd. announced that they will report Q3, 2024 results on Oct 25, 2024
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 30%After last week's 30% share price gain to CN¥23.85, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 26% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥13.33 per share.
Reported Earnings • Aug 20Second quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.063 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.14 (up from CN¥0.063 in 2Q 2023). Revenue: CN¥810.8m (up 32% from 2Q 2023). Net income: CN¥136.3m (up 123% from 2Q 2023). Profit margin: 17% (up from 10.0% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
お知らせ • Jun 29Hubei Dinglong CO.,Ltd. to Report First Half, 2024 Results on Aug 20, 2024Hubei Dinglong CO.,Ltd. announced that they will report first half, 2024 results on Aug 20, 2024
Reported Earnings • Apr 26First quarter 2024 earnings released: EPS: CN¥0.086 (vs CN¥0.037 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.086 (up from CN¥0.037 in 1Q 2023). Revenue: CN¥708.0m (up 30% from 1Q 2023). Net income: CN¥81.6m (up 135% from 1Q 2023). Profit margin: 12% (up from 6.4% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.
Major Estimate Revision • Apr 16Consensus EPS estimates fall by 14%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥3.27b to CN¥3.16b. EPS estimate also fell from CN¥0.508 per share to CN¥0.438 per share. Net income forecast to grow 86% next year vs 44% growth forecast for Chemicals industry in China. Consensus price target up from CN¥22.75 to CN¥25.50. Share price fell 6.7% to CN¥20.12 over the past week.
Price Target Changed • Apr 11Price target increased by 7.7% to CN¥24.50Up from CN¥22.75, the current price target is an average from 2 analysts. New target price is 19% above last closing price of CN¥20.55. Stock is down 19% over the past year. The company is forecast to post earnings per share of CN¥0.43 for next year compared to CN¥0.24 last year.
お知らせ • Apr 10Hubei Dinglong CO.,Ltd., Annual General Meeting, May 14, 2024Hubei Dinglong CO.,Ltd., Annual General Meeting, May 14, 2024, at 15:00 China Standard Time. Location: The Company's Meeting Room, Wuhan, Hubei China
Reported Earnings • Apr 10Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: EPS: CN¥0.24 (down from CN¥0.42 in FY 2022). Revenue: CN¥2.67b (down 2.0% from FY 2022). Net income: CN¥222.0m (down 43% from FY 2022). Profit margin: 8.3% (down from 14% in FY 2022). The decrease in margin was primarily driven by higher expenses. Revenue missed analyst estimates by 3.3%. Earnings per share (EPS) also missed analyst estimates by 4.7%. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.
お知らせ • Mar 30Hubei Dinglong CO.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024Hubei Dinglong CO.,Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024
Buy Or Sell Opportunity • Mar 26Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 10% to CN¥21.51. The fair value is estimated to be CN¥27.39, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 73%. Revenue is forecast to grow by 40% in 2 years. Earnings are forecast to grow by 116% in the next 2 years.
お知らせ • Mar 16Hubei Dinglong CO.,Ltd. (SZSE:300054) agreed to acquire 6.83% stake in Wuhan Rouxian Technology Co., Ltd. from Qushui Dinglong Taihao Enterprise Management Co., Ltd. managed by Wuhan Paradise Silicon Valley Technology Innovation Asset Management Co., Ltd. for CNY 31.9 million.Hubei Dinglong CO.,Ltd. (SZSE:300054) agreed to acquire 6.83% stake in Wuhan Rouxian Technology Co., Ltd. from Qushui Dinglong Taihao Enterprise Management Co., Ltd. managed by Wuhan Paradise Silicon Valley Technology Innovation Asset Management Co., Ltd. for CNY 31.9 million on March 13, 2024. Transaction was financed by Hubei Dinglong's own funds. Transaction has already been approved by Wuhan Rouxian Technology Co., Ltd's board of director's.
Valuation Update With 7 Day Price Move • Feb 08Investor sentiment improves as stock rises 17%After last week's 17% share price gain to CN¥20.42, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 13x in the Chemicals industry in China. Negligible returns to shareholders over past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥27.64 per share.
お知らせ • Feb 07Hubei Dinglong CO.,Ltd. (SZSE:300054) announces an Equity Buyback for CNY 200 million worth of its shares.Hubei Dinglong CO.,Ltd. (SZSE:300054) announces a share repurchase program. Under the program, the company will repurchase up to CNY 200 million worth of its shares. The shares will be repurchased at a price not more than CNY 30 per share. The purpose of the program is to use the repurchased shares for ESOP or equity incentives. The program is valid for a period of 3 months.
Price Target Changed • Feb 02Price target decreased by 8.1% to CN¥22.75Down from CN¥24.75, the current price target is an average from 2 analysts. New target price is 37% above last closing price of CN¥16.61. Stock is down 29% over the past year. The company is forecast to post earnings per share of CN¥0.25 for next year compared to CN¥0.42 last year.
Major Estimate Revision • Jan 25Consensus EPS estimates fall by 20%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from CN¥0.32 to CN¥0.255. Revenue forecast unchanged from CN¥2.77b at last update. Net income forecast to grow 59% next year vs 59% growth forecast for Chemicals industry in China. Consensus price target down from CN¥25.50 to CN¥24.75. Share price fell 2.4% to CN¥19.26 over the past week.
お知らせ • Dec 30Hubei Dinglong CO.,Ltd. to Report Fiscal Year 2023 Results on Apr 10, 2024Hubei Dinglong CO.,Ltd. announced that they will report fiscal year 2023 results on Apr 10, 2024
Reported Earnings • Oct 26Third quarter 2023 earnings released: EPS: CN¥0.093 (vs CN¥0.10 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.093 (down from CN¥0.10 in 3Q 2022). Revenue: CN¥713.2m (up 11% from 3Q 2022). Net income: CN¥80.4m (down 20% from 3Q 2022). Profit margin: 11% (down from 16% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.
お知らせ • Sep 30Hubei Dinglong CO.,Ltd. to Report Q3, 2023 Results on Oct 26, 2023Hubei Dinglong CO.,Ltd. announced that they will report Q3, 2023 results on Oct 26, 2023
Major Estimate Revision • Aug 25Consensus EPS estimates fall by 12%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from CN¥3.19b to CN¥3.06b. EPS estimate also fell from CN¥0.533 per share to CN¥0.467 per share. Net income forecast to grow 80% next year vs 53% growth forecast for Chemicals industry in China. Consensus price target down from CN¥30.00 to CN¥27.50. Share price fell 4.5% to CN¥20.46 over the past week.
Price Target Changed • Aug 22Price target decreased by 8.3% to CN¥27.50Down from CN¥30.00, the current price target is an average from 4 analysts. New target price is 27% above last closing price of CN¥21.65. Stock is down 15% over the past year. The company is forecast to post earnings per share of CN¥0.50 for next year compared to CN¥0.42 last year.
Reported Earnings • Aug 19Second quarter 2023 earnings released: EPS: CN¥0.063 (vs CN¥0.13 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.063 (down from CN¥0.13 in 2Q 2022). Revenue: CN¥612.7m (down 18% from 2Q 2022). Net income: CN¥61.1m (down 50% from 2Q 2022). Profit margin: 10.0% (down from 17% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
お知らせ • Jul 01Hubei Dinglong CO.,Ltd. to Report First Half, 2023 Results on Aug 19, 2023Hubei Dinglong CO.,Ltd. announced that they will report first half, 2023 results on Aug 19, 2023
お知らせ • Jun 09Hubei Dinglong Co.,Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on June 16, 2023Hubei Dinglong CO.,Ltd. announced final cash dividend/10 shares (tax included) of CNY 0.50000000 on A shares for the year 2022. Record date is June 15, 2023. Ex-date is May June 16, 2023. Payment date is June 16, 2023.
Valuation Update With 7 Day Price Move • Apr 20Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥29.90, the stock trades at a forward P/E ratio of 51x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 162% over the past three years.
Reported Earnings • Apr 12Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: EPS: CN¥0.42 (up from CN¥0.23 in FY 2021). Revenue: CN¥2.72b (up 16% from FY 2021). Net income: CN¥390.0m (up 83% from FY 2021). Profit margin: 14% (up from 9.1% in FY 2021). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 4.2%. Earnings per share (EPS) also missed analyst estimates by 3.7%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth.
Price Target Changed • Jan 11Price target increased to CN¥27.75Up from CN¥25.92, the current price target is an average from 2 analysts. New target price is 26% above last closing price of CN¥21.96. Stock is down 1.6% over the past year. The company is forecast to post earnings per share of CN¥0.42 for next year compared to CN¥0.23 last year.
Board Change • Nov 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Independent Director Minguang Su was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 27Third quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.062 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.10 (up from CN¥0.062 in 3Q 2021). Revenue: CN¥642.9m (up 16% from 3Q 2021). Net income: CN¥100.3m (up 70% from 3Q 2021). Profit margin: 16% (up from 11% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 31% per year whereas the company’s share price has increased by 33% per year.
Valuation Update With 7 Day Price Move • Oct 11Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to CN¥19.19, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 14x in the Chemicals industry in China. Total returns to shareholders of 108% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥17.38 per share.
Valuation Update With 7 Day Price Move • Sep 07Investor sentiment improved over the past weekAfter last week's 17% share price gain to CN¥26.51, the stock trades at a forward P/E ratio of 52x. Average forward P/E is 17x in the Chemicals industry in China. Total returns to shareholders of 154% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥19.08 per share.
Reported Earnings • Aug 20Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.058 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.14 (up from CN¥0.058 in 2Q 2021). Revenue: CN¥742.8m (up 29% from 2Q 2021). Net income: CN¥123.1m (up 129% from 2Q 2021). Profit margin: 17% (up from 9.3% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 29%, compared to a 41% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 38% per year, which means it is well ahead of earnings.
お知らせ • Jun 18Hubei Dinglong Co.,Ltd. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on June 24, 2022Hubei Dinglong CO.,Ltd. announced 2021 final profit distribution plan to be implemented (A shares), Payable on June 24, 2022. The company announced Cash dividend/10 shares (tax included) of CNY 0.20000000. The record date is June 23, 2022 and ex-date is June 24, 2022.
Board Change • Jun 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Independent Director Minguang Su was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 12+ 1 more updateHubei Dinglong CO.,Ltd. Announces Executive ChangesHubei Dinglong CO.,Ltd. at the AGM, the shareholders approved election of Zhu Shuangquan, Zhu Shunquan, Yang Bo, Yao Hong, Yang Pingcai, Su Minguang. The following election and nomination of independent directors, cumulative voting system applicable: Huang Jing, Yu Minggui, Wang Xiongyuan.
Reported Earnings • Apr 27First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2022 results: EPS: CN¥0.076 (up from CN¥0.04 in 1Q 2021). Revenue: CN¥569.7m (up 9.6% from 1Q 2021). Net income: CN¥71.4m (up 90% from 1Q 2021). Profit margin: 13% (up from 7.2% in 1Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 4.1%. Earnings per share (EPS) missed analyst estimates by 16%. Over the next year, revenue is forecast to grow 29%, compared to a 43% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. 3 independent directors (8 non-independent directors). Independent Director Xiao Ji was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Apr 23Hubei Dinglong CO.,Ltd. (SZSE:300054) announces an Equity Buyback for CNY 400 million worth of its shares.Hubei Dinglong CO.,Ltd. (SZSE:300054) announces a share repurchase program. Under the program, the company will repurchase up to CNY 400 million worth of its shares. The program is valid for a period of 12 months.
お知らせ • Apr 16+ 1 more updateHubei Dinglong CO.,Ltd. Announces Profit Distribution Proposal for 2021Hubei Dinglong CO.,Ltd. announced on 15 April 2022 Cash dividend/10 shares (tax included) of CNY 0.20000000 for 2021.
Reported Earnings • Apr 16Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: EPS: CN¥0.23 (up from CN¥0.17 loss in FY 2020). Revenue: CN¥2.36b (up 30% from FY 2020). Net income: CN¥213.5m (up CN¥373.3m from FY 2020). Profit margin: 9.1% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 4.1%. Earnings per share (EPS) missed analyst estimates by 16%. Over the next year, revenue is forecast to grow 15%, compared to a 51% growth forecast for the industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 105 percentage points per year, which is a significant difference in performance.
お知らせ • Nov 24Hubei Dinglong CO.,Ltd. announced that it expects to receive CNY 210.5 million in funding from CCB Trust Co., Ltd.Hubei Dinglong CO.,Ltd. announced a private placement of common shares for a gross proceeds of CNY 210,500,000 on November 22, 2021. The transaction will include participation from CCB Trust Co., Ltd. Post transaction, the investor will hold a stake of 8%.
Reported Earnings • Oct 28Third quarter 2021 earnings released: EPS CN¥0.062 (vs CN¥0.04 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥554.9m (up 25% from 3Q 2020). Net income: CN¥59.2m (up 45% from 3Q 2020). Profit margin: 11% (up from 9.2% in 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 158 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 19Second quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.18 in 2Q 2020)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥576.4m (up 9.2% from 2Q 2020). Net income: CN¥53.9m (down 71% from 2Q 2020). Profit margin: 9.3% (down from 35% in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 139 percentage points per year, which is a significant difference in performance.
Reported Earnings • Apr 10Full year 2020 earnings released: CN¥0.17 loss per share (vs CN¥0.036 profit in FY 2019)The company reported a mediocre full year result with weaker earnings and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: CN¥1.82b (up 58% from FY 2019). Net loss: CN¥159.8m (down CN¥193.9m from profit in FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 82 percentage points per year, which is a significant difference in performance.
お知らせ • Feb 24Hubei Dinglong CO.,Ltd. to Report Fiscal Year 2020 Results on Apr 10, 2021Hubei Dinglong CO.,Ltd. announced that they will report fiscal year 2020 results on Apr 10, 2021
Is New 90 Day High Low • Jan 21New 90-day high: CN¥23.44The company is up 52% from its price of CN¥15.38 on 23 October 2020. The Chinese market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 19% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥12.87 per share.